We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Shooting up

9 January 2012 By Robert Cyran

Bristol-Myers will pay a 163 pct premium for Inhibitex. Recent bids for other hepatitis C specialists have also gone skyward. In any hot biotech field, there are few targets and most have insiders with big stakes. Satisfying their belief in their efforts is what drives prices up.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)